Oncology

Latest News

close-up of a clock minute, hour and second hands | Image credit: ©blackday stock.adobe.com
Another Toxicity of Cancer Treatment

July 8th 2024

Time can be especially precious for people with advanced cancer. Researchers and clinicians are beginning to consider “time toxicity” as another aspect of treatment that burdens patients and their loved ones.

FDA Approves Breyanzi for Mantle Cell Lymphoma
FDA Approves Breyanzi for Mantle Cell Lymphoma

May 31st 2024

Science RF-stock.adobe.com
Verastem Begins Submission for Ovarian Cancer Combination

May 24th 2024

appledesign-stock.adobe.com
FDA Approves Bispecific Antibody for Small Cell Lung Cancer

May 17th 2024

FDA Approves Breyanzi for Follicular Lymphoma
FDA Approves Breyanzi for Follicular Lymphoma

May 16th 2024

Video Series
Video Interviews
Podcasts
Latest CME Events & Activities

Expanding the Armamentarium of Actionable Mutations in NSCLC: Uncovering the Potential of CEACAM5 as a Therapeutic Target

View More

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

View More

Pathology Implications for CEACAM5 as a Therapeutic Target in Advanced NSCLC

View More

Medical Crossfire®: What Are Effective Strategies for Onco-Nurses to Improve Outcomes in Patients with Small Cell Lung Cancer?

View More

Virtual Show Me the Data™: How HER2, HER3, and TROP2 Targeted Strategies Will Impact Evolving Paradigms in NSCLC

View More

42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®

November 13-15, 2024

Register Now!

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities

View More

Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!

View More

22nd Annual Winter Lung Cancer Conference®

January 31, 2025 - February 2, 2025

Register Now!

Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…

View More

More News

© 2024 MJH Life Sciences

All rights reserved.